The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease: A Meta-analysis of Randomized Trials
Abstract
CONTEXT: Randomized trials have shown that aspirin decreases the risk of cardiovascular events in patients with symptomatic coronary and cerebrovascular disease. Despite guideline recommendations for secondary prevention in peripheral artery disease (PAD), the effect of aspirin in this population is not well established. OBJECTIVE: To investigate the effect of aspirin on cardiovascular event rates in patients with PAD. DATA SOURCES AND STUDY SELECTION: MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, Science Citation Index (1966 to December 2008), and unpublished studies from the supplemental index of the Antithrombotic Trialists' Collaboration. Eligible studies were prospective, randomized controlled trials of aspirin therapy, with or without dipyridamole that reported cardiovascular event rates. Eighteen trials involving 5269 individuals were identified. DATA EXTRACTION: Studies were reviewed to determine the number of participants, mean follow-up, and the primary end point of cardiovascular events (nonfatal myocardial infarction [MI], nonfatal stroke, and cardiovascular death). Data on the secondary end points of all-cause mortality, major bleeding, and the individual components of the primary outcome measure were also abstracted. For the primary end point, the analysis had 88% power to detect a 25% reduction and 70% power to detect a 20% reduction in cardiovascular events in the aspirin group compared with the control group. DATA SYNTHESIS: Among 5269 participants, cardiovascular events were experienced by 251 (8.9%) of 2823 patients taking aspirin (alone or with dipyridamole) and by 269 (11.0%) of 2446 in the control group (pooled relative risk [RR], 0.88; 95% confidence interval [CI], 0.76-1.04). Aspirin therapy was associated with a reduction in the secondary outcome of nonfatal stroke (52 of 2823 vs 76 of 2446; RR, 0.66; 95% CI, 0.47-0.94) but was not associated with significant reductions in all-cause or cardiovascular mortality, MI, or major bleeding. In the subset of 3019 participants taking aspirin alone vs control, aspirin was associated with a nonsignificant reduction in cardiovascular events (125 of 1516 vs 144 of 1503; RR, 0.75; 95% CI, 0.48-1.18), a significant reduction in nonfatal stroke (32 of 1516 vs 51 of 1503; RR, 0.64; 95% CI, 0.42-0.99), but no statistically significant reductions in all-cause or cardiovascular mortality, MI, or major bleeding. CONCLUSIONS: In patients with PAD, treatment with aspirin alone or with dipyridamole resulted in a statistically nonsignificant decrease in the primary end point of cardiovascular events and a significant reduction in nonfatal stroke. Results for the primary end point may reflect limited statistical power. Additional randomized controlled trials of aspirin therapy are needed to establish the net benefit and bleeding risks in PAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. R. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.037 · Cited by 8,191
Self-citationCollaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174526 · Cited by 3,708
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Quantitative Synthesis in Systematic Reviews
Lau, J., Ioannidis, J. P. A., & Schmid, C. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-9-199711010-00008 · Cited by 2,517 · cited 1×
“The Cochran Q statistic and I(2) statistic were calculated to assess the degree of heterogeneity among the trials.(18) The Q statisticdidnot indicate statistically significant heterogeneity for any end point.”
MethodKjaergard, L. L., Villumsen, J., & Gluud, C. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00010 · Cited by 2,283
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
One-year cardiovascular event rates in outpatients with atherothrombosis
Steg, P. G., Bhatt, D. L., Wilson, P. W. F., D’Agostino, R., Ohman, E. M., Röther, J., Liau, C.-S., Hirsch, A. T., Mas, J.-L., Ikeda, Y., et al. (2007) · JAMA · doi:10.1001/jama.297.11.1197 · Cited by 1,382
Chen, Z.-M. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04010-5 · Cited by 1,232
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Peripheral Arterial Disease: Morbidity and Mortality Implications
Golomb, B. A., Dang, T. T., & Criqui, M. H. (2006) · Circulation · doi:10.1161/circulationaha.105.593442 · Cited by 498
Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Campbell, C. L., Smyth, S., Montalescot, G., & Steinhubl, S. R. (2007) · JAMA · doi:10.1001/jama.297.18.2018 · Cited by 444
Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa065959 · Cited by 442
Random-Effects Meta-Analyses Are Not Always Conservative
Poole, C., & Greenland, S. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010035 · Cited by 338
Medical Treatment of Peripheral Arterial Disease
Hankey, G. J. (2006) · JAMA · doi:10.1001/jama.295.5.547 · Cited by 332
Andreotti, F., Testa, L., Biondi-Zoccai, G. G. L., & Crea, F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi485 · Cited by 289
Hess, H., Mietaschk, A., & Deichsel, G. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91144-4 · Cited by 258
Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis
Berger, J. S., Brown, D. L., & Becker, R. C. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.10.002 · Cited by 203
Self-citationCritical Leg Ischaemia Prevention Study (CLIPS) Group (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01763.x · Cited by 202
Lowe, G. D. O., Yarnell, J. W. G., Rumley, A., Bainton, D., & Sweetnam, P. M. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.4.603 · Cited by 199
Tran, H. (2004) · JAMA · doi:10.1001/jama.292.15.1867 · Cited by 181
Antithrombotic Therapy for Peripheral Artery Occlusive Disease
Sobel, M., & Verhaeghe, R. (2008) · Chest · doi:10.1378/chest.08-0686 · Cited by 174
Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study
Goldhaber, S. Z., Manson, J. E., Stampfer, M. J., LaMotte, F., Rosner, B., Buring, J. E., & Hennekens, C. H. (1992) · The Lancet · doi:10.1016/0140-6736(92)93216-a · Cited by 167
Brevetti, G., Schiano, V., & Chiariello, M. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.002 · Cited by 165
NERISERNERI, G., COCCHERI, S., Marubini, E., & Violi, F. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.07.013 · Cited by 140
Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial
McCollum, C. N., Alexander, C., Kenchington, G., Franks, P. J., & Greenhalgh, R. M. (1991) · Journal of Vascular Surgery · doi:10.1016/0741-5214(91)90022-m · Cited by 131
Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency.
Rm, G., Roedersheimer, L. R., & DeWeese, J. A. (1982) · PubMed · Cited by 130
Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts.
Tr, K., Kaufman, J. L., Kacoyanis, G. P., Clowes, A. W., Mc, D., Kelly, E., Skillman, J. J., Np, C., Whittemore, A. D., & Mannick, J. A. (1984) · PubMed · Cited by 127
McDermott, M. M., Greenland, P., Green, D., Guralnik, J. M., Criqui, M. H., Liu, K., Chan, C., Pearce, W. H., Taylor, L. M., Ridker, P. M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000074227.53616.cc · Cited by 126
Pande, R. L., Perlstein, T. S., Beckman, J. A., & Creager, M. A. (2008) · Circulation · doi:10.1161/circulationaha.107.721878 · Cited by 92
Adiponectin and inflammatory markers in peripheral arterial occlusive disease
Iwashima, Y., Horio, T., Suzuki, Y., Kihara, S., Rakugi, H., Kangawa, K., Funahashi, T., Ogihara, T., & Kawano, Y. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.039 · Cited by 70
Reocclusion Prophylaxis with Dipyridamole Combined with Acetylsalicylic Acid Following PTA
Heiss, H., Just, H., Middleton, D., & Deichsel, G. (1990) · Angiology · doi:10.1177/000331979004100402 · Cited by 60
Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke
O'Donnell, M. J., Hankey, G. J., & Eikelboom, J. W. (2008) · Stroke · doi:10.1161/strokeaha.107.497271 · Cited by 44
The Influence of Platelet Inhibition on the Patency of Femoro-Popliteal Dacron Bypass Grafts
Donaldson, D. M., Salter, M. C. P., Kester, R. C., Rajah, S. M., Hall, T., Sreeharan, N., & Crow, M. J. (1985) · Vascular Surgery · doi:10.1177/153857448501900405 · Cited by 44
GOLDMAN, M. D., & McCollum, C. N. (1984) · Vascular Surgery · doi:10.1177/153857448401800404 · Cited by 32
Lee, W., Sheu, W. H., Chen, Y., Liu, T.-J., Liang, K., Ting, C.-T., & Lee, W.-L. (2005) · Thrombosis Research · doi:10.1016/j.thromres.2005.10.012 · Cited by 29
Kudoh, T., Sakamoto, T., Miyamoto, S., Matsui, K., Kojima, S., Sugiyama, S., Yoshimura, M., Ozaki, Y., & Ogawa, H. (2005) · Thrombosis Research · doi:10.1016/j.thromres.2005.03.011 · Cited by 16
Colwell, J. A., Bingham, S. F., Abraira, C., Anderson, J. W., Comstock, J. P., Kwaan, H. C., & Nuttall, F. Q. (1989) · Journal of Diabetes and its Complications · doi:10.1016/0891-6632(89)90029-9 · Cited by 12
Cited by
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.007 · Cited by 1,941
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000470 · Cited by 1,055
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000471 · Cited by 1,020
Metadata
- Authors
- Berger, J. S., Krantz, M. J., Kittelson, J. M., & Hiatt, W. R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-05-13
- Volume
- 301
- Issue
- 18
- Pages
- 1909
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2078349288
- Cited by
- 360
- References
- 42
- FWCI
- 21.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.